

John E. Flaherty  
Ravin R. Patel  
McCARTER & ENGLISH LLP  
Four Gateway Center  
100 Mulberry Street  
Newark, New Jersey 07102  
(973) 622-4444

*Counsel for Plaintiffs Takeda GmbH,  
AstraZeneca Pharmaceuticals LP, and  
AstraZeneca UK Limited.*

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

---

TAKEDA GMBH, ASTRAZENECA  
PHARMACEUTICALS LP, AND  
ASTRAZENECA UK LIMITED,

Plaintiffs,

v.

TORRENT PHARMA INC. AND  
TORRENT PHARMACEUTICALS LTD.,

Defendants.

---

Civil Action No. \_\_\_\_\_

**COMPLAINT**

Plaintiffs Takeda GmbH (“Takeda”), AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited (collectively, “AstraZeneca”) (Takeda and AstraZeneca, collectively, “Plaintiffs”), by its attorneys, hereby allege as follows:

**NATURE OF THE ACTION**

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, against Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. (collectively, “Torrent”). This action relates to Abbreviated New Drug

Application (“ANDA”) No. 208272 filed by Torrent with the U.S. Food and Drug Administration (“FDA”).

2. In ANDA No. 208272, Torrent seeks approval to market 500 mcg tablets of roflumilast, generic versions of Plaintiffs’ Daliresp<sup>®</sup> drug product (the “Torrent ANDA product”), prior to expiration of U.S. Patent No. 5,712,298 (the “’298 patent”).

### **PARTIES**

3. Takeda GmbH is a corporation organized and existing under the laws of Germany, having its principal place of business at Byk-Gulden-Strasse 2, 78467 Konstanz, Germany.

4. AstraZeneca Pharmaceuticals LP is a limited partnership organized under the laws of Delaware, having its principal place of business at 1800 Concord Pike, Wilmington, Delaware 19803.

5. AstraZeneca UK Limited is a company incorporated under the Laws of England and Wales, having a registered office at 2 Kingdom Street, London, England W2 6BD.

6. Plaintiffs are engaged in the business of creating, developing, and bringing to market revolutionary pharmaceutical products to help patients prevail against serious diseases, including treatments for Chronic Obstructive Pulmonary Disease (“COPD”). AstraZeneca markets and sells Daliresp<sup>®</sup> in this judicial district and throughout the United States.

7. Upon information and belief, Torrent Pharmaceuticals Ltd. is a corporation organized and existing under the laws of India, having its principal place of business at Torrent House, Off Ashram Road, Ahmedabad, 380009, Gujarat, India.

8. Upon information and belief, Torrent Pharma Inc. is a corporation organized and existing under the laws of Delaware with its corporate headquarters at 150 Allen Road, Suite 102, Basking Ridge, New Jersey 07920.

9. Upon information and belief, Torrent Pharma Inc. is a wholly-owned subsidiary of Torrent Pharmaceuticals Ltd.

### **JURISDICTION AND VENUE**

10. This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, *et seq.*, and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

11. Venue is proper in this Court under 28 U.S.C. §§ 1391 and 1400(b).

12. This Court has jurisdiction over Torrent because, upon information and belief, Torrent Pharma Inc. has its corporate headquarters in New Jersey and is the subsidiary and agent of Torrent Pharmaceuticals Ltd. Upon information and belief, Torrent Pharma Inc. is acting as the agent of Torrent Pharmaceuticals Ltd. with respect to ANDA No. 208272.

13. In the alternative, this Court has jurisdiction over Torrent Pharmaceuticals Ltd. because the requirements of Federal Rule of Civil Procedure 4(k)(2)(A) are met.

14. This Court also has jurisdiction over Torrent Pharmaceuticals Ltd. because, *inter alia*, this action arises from actions of Torrent Pharmaceuticals Ltd. directed toward New Jersey, and because Torrent Pharmaceuticals Ltd. has purposefully availed itself of the rights and benefits of New Jersey law by engaging in systematic and continuous contacts with New Jersey. Upon information and belief, Torrent Pharmaceuticals Ltd. regularly and continuously transacts business within the State of New Jersey, including by selling pharmaceutical products in New Jersey, either on its own or through its wholly-owned subsidiary Torrent Pharma Inc. Upon information and belief, Torrent Pharma Inc.'s corporate headquarters is located in Basking Ridge, New Jersey. Upon information and belief, Torrent Pharmaceuticals Ltd. derives substantial revenue from the sale of those products in New Jersey and has availed itself of the privilege of conducting business within the State of New Jersey.

15. This Court also has jurisdiction over Torrent Pharma Inc. because, *inter alia*, upon information and belief, Torrent Pharma Inc.'s corporate headquarters is located in Basking Ridge, New Jersey. Upon information and belief, Torrent Pharma Inc., directly or indirectly, manufactures, imports, markets, and sells generic drugs throughout the United States and in this judicial district.

16. Torrent has previously been sued in this judicial district without objecting on the basis of lack of personal jurisdiction, including in the case captioned *Takeda GmbH et al. v. Torren Pharma Inc., et al.*, No. 3:15-cv-3375 (D.N.J. filed May 15, 2015), and has availed itself of New Jersey courts through the assertion of counterclaims in suits brought in New Jersey.

17. For these reasons, and for other reasons that will be presented to the Court if jurisdiction is challenged, the Court has personal jurisdiction over Torrent.

#### **PATENT-IN-SUIT**

18. On January 27, 1998, the U.S. Patent and Trademark Office duly and legally issued the '298 patent, titled "Fluoroalkoxy-Substituted Benzamides And Their Use As Cyclic Nucleotide Phosphodiesterase Inhibitors." A true and correct copy of the '298 patent is attached hereto as Exhibit A. The claims of the '298 patent are valid and enforceable. Takeda is the owner of the '298 patent and has the right to enforce it. The expiration date of the '298 patent is January 27, 2020.

19. AstraZeneca UK Limited is the exclusive licensee of the '298 patent in the United States. AstraZeneca UK Limited is also the holder of New Drug Application ("NDA") No. 022522, by which the FDA granted approval for the marketing and sale of 500 mcg strength roflumilast tablets. AstraZeneca markets roflumilast tablets in the United States, under the trade name "Daliresp<sup>®</sup>." The FDA's official publication of approved drugs (the "Orange Book") includes Daliresp<sup>®</sup> together with the '298 patent. Daliresp<sup>®</sup> is approved as a treatment

to reduce the risk of COPD exacerbation in patients with severe COPD associated with chronic bronchitis and a history of exacerbation. A copy of the complete prescribing information for Daliresp<sup>®</sup> approved in NDA No. 022522 is attached as Exhibit B.

20. AstraZeneca Pharmaceuticals LP is authorized by the patent licensee, AstraZeneca UK Limited, to market and distribute Daliresp<sup>®</sup> in the United States.

### **INFRINGEMENT BY TORRENT**

21. By letter sent on April 8, 2016 by Federal Express, Torrent notified AstraZeneca and Nycomed Germany Holding GmbH that Torrent had submitted ANDA No. 208272 to the FDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)) (“the Daliresp Notice Letter”). Takeda and AstraZeneca received the Daliresp Notice Letter by April 11, 2016.

22. The Daliresp Notice Letter states that Torrent seeks approval from the FDA to engage in the commercial manufacture, use, and sale of the Torrent ANDA product before the expiration of the ’298 patent. Upon information and belief, Torrent intends to – directly or indirectly – engage in the commercial manufacture, use, and sale of the Torrent ANDA product promptly upon receiving FDA approval to do so.

23. By filing ANDA No. 208272, Torrent has necessarily represented to the FDA that the Torrent ANDA product has the same active ingredient as Daliresp<sup>®</sup>, has the same method of administration, dosage form, and strength as Daliresp<sup>®</sup>, and is bioequivalent to Daliresp<sup>®</sup>.

24. In the Daliresp Notice Letter, Torrent states that its ANDA contains a Paragraph IV certification asserting that the ’298 patent is invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, and sale of the Torrent ANDA product.

25. This Complaint is being filed before the expiration of forty-five days from the date Plaintiffs received the Daliresp Notice Letter.

**COUNT I**

**(INFRINGEMENT OF THE '298 PATENT)**

26. Each of the preceding paragraphs 1 to 25 is incorporated as if fully set forth herein.

27. Torrent's submission of ANDA No. 208272 to obtain approval to engage in the commercial manufacture, use, offer to sell, or sale of the Torrent ANDA product prior to the expiration of the '298 patent constituted a technical act of infringement of one or more of the claims of the '298 patent under 35 U.S.C. § 271(e)(2)(A).

28. Torrent's commercial manufacture, use, offer to sell, sale, or importation of the Torrent ANDA product prior to the expiration of the '298 patent, and its inducement of and/or contribution to such conduct, would further infringe one or more claims of the '298 patent under 35 U.S.C. §§ 271(a), (b) and/or (c).

29. Upon FDA approval of Torrent's ANDA No. 208272, Torrent will infringe one or more claims of the '298 patent by making, using, offering to sell, and selling the Torrent ANDA product in the United States and/or importing said product into the United States, or by actively inducing and contributing to infringement of the '298 patent by others, under 35 U.S.C. § 271(a)-(c), unless enjoined by the Court.

30. If Torrent's marketing and sale of the Torrent ANDA product prior to expiration of the '298 patent and all other relevant exclusivities are not enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no remedy at law.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray that this Court grant the following relief:

1. A judgment that the claims of the '298 patent are not invalid, are not unenforceable, and are infringed by Torrent's submission of ANDA No. 208272, and that

Torrent's making, using, offering to sell, or selling in the United States, or importing into the United States the Torrent ANDA product will infringe the '298 patent.

2. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any approval of ANDA No. 208272 shall be a date which is not earlier than the expiration date of the '298 patent, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled.

3. An order permanently enjoining Torrent, its affiliates, subsidiaries, and each of its officers, agents, servants and employees and those acting in privity or concert with them, from making, using, offering to sell, or selling in the United States, or importing into the United States the Torrent ANDA product until after the expiration date of the '298 patent, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled.

4. Damages or other monetary relief to Plaintiffs if Torrent engages in commercial manufacture, use, offers to sell, sale, or importation in or into the United States of the Torrent ANDA product prior to the expiration date of the '298 patent, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled.

5. Such further and other relief as this Court deems proper and just, including any appropriate relief under 35 U.S.C. § 285.

Dated: April 13, 2016

Respectfully Submitted,

s/ John E. Flaherty

John E. Flaherty

Ravin R. Patel

McCARTER & ENGLISH LLP

Four Gateway Center

100 Mulberry Street

Newark, NJ 07102  
(973) 639-7903  
jflaherty@mccarter.com

*Attorneys for Takeda GmbH, AstraZeneca  
Pharmaceuticals LP, and AstraZeneca UK  
Limited*



**CERTIFICATION PURSUANT TO L. CIV. R. 11.2**

Pursuant to Local Civil Rule 11.2, I hereby certify that the matter in controversy is the subject of the following actions:

- *IN RE: CERTAIN CONSOLIDATED ROFLUMILAST CASES*, Consolidated Action No. 3:15-cv-3375-FLW-DEA  
(Consolidated with Civil Action Nos. 3:15-cv-03376-FLW-DEA, 3:15-cv-03377-FLW-DEA, 3:15-cv-03378-FLW-DEA, 3:15-cv-03379-FLW-DEA, 3:15-cv-03380-FLW-DEA, 3:15-cv-03382-FLW-DEA, 3:15-cv-03383-FLW-DEA, 3:15-cv-03384-FLW-DEA, 3:15-cv-03385-FLW-DEA, 3:15-cv-07921-FLW-DEA, 3:15-cv-08492-FLW-DEA, 3:16-cv-1280-FLW-DEA).

Dated: April 13, 2016

Respectfully Submitted,

s/ John E. Flaherty

John E. Flaherty

Ravin R. Patel

MCCARTER & ENGLISH LLP

Four Gateway Center

100 Mulberry Street

Newark, NJ 07102

(973) 639-7903

jflaherty@mccarter.com

*Attorneys for Takeda GmbH, AstraZeneca  
Pharmaceuticals LP, and AstraZeneca UK  
Limited*